PMGC Holdings Inc. Initiates Phase II Collaboration for AI-Driven Therapies NEWPORT BEACH, Calif., June 17, 2025 - PMGC Holdings Inc., through its subsidiary Northstrive Biosciences, has announced the initiation of Phase II of its AI Development Program in collaboration with Yuva Biosciences, Inc. The collaboration aims to leverage YuvaBio's MitoNova™ platform, a mitochondrial science-focused AI tool, to identify small molecule candidates that enhance mitochondrial health in obesity and cardiac diseases. The program will involve virtual screening of a diverse library of drug-like small molecules to predict their potential in promoting mitochondrial health. The results of this screening will be analyzed to identify opportunities for biological validation. No results have been presented yet; these will follow the completion of the screening and analysis process.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.